Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer

GlaxoSmithKline156 enrolled

Overview

This study aims to analyze the incidence of expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer.

There will be no procedure(s) or treatment(s) carried out on patients. All data and samples will be taken from those already stored at the investigation sites. Clinical data collected will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system) \[TNM stage\], and histopathologic description only. Strict anonymity of patient data will be maintained. This retrospective study is based upon the analysis of archived formalin-fixed paraffin-embedded tissue samples and patient-related data already available at the investigational site.

Study Type

OBSERVATIONAL

Enrollment

156

Conditions

Neoplasms, Urinary Bladder

Interventions

Data acquisition and analysisOTHER

Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: For inclusion of a tissue sample, all of the following criteria must be met: * The patient had pathologically proven bladder cancer (any stage). * All the data required are available from patient's records. There are no restrictions regarding operative technique (cystectomy or cystoscopy). \- Many patients may no longer be alive, or no longer be in contact with the investigation sites. Thus, patients will not be required to give their informed consent before inclusion in the study. Exclusion Criteria: * Not applicable.

Locations (1)

GSK Investigational Site

Leuven, Belgium

Outcomes

Primary Outcomes

To determine the gene expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in pathologically demonstrated bladder cancer.

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.